A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

Immunotherapy has revolutionized the way physicians treat patients with cancer. This form of cancer treatment aims to direct the immune system toward the r | Immunology ...

The start of patient dosing represents a huge milestone for Moleculin and, importantly, the AML community. “Our team rem ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...

Initial data readout on track for second half of 2025HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...